代谢基因，透明细胞肾细胞癌预后和免疫原性的潜在预测指标。
Metabolic genes, a potential predictor of prognosis and immunogenicity of clear cell renal cell carcinoma.
作者信息
Ji Cheng-Jian, Wei Xi-Yi, Yao Liang-Yu, Wang Yi-Chun, Cong Rong, Song Ning-Hong
机构信息
Department of Urology, The First Affiliated Hospital of Nanjing Medical University Nanjing 210029, Jiangsu, China.
The Affiliated Kezhou People's Hospital of Nanjing Medical University Kezhou 845350, Xinjiang, China.
出版信息
Am J Cancer Res. 2023 Apr 15;13(4):1387-1406. eCollection 2023.
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC). Many ccRCCs are diagnosed at an advanced stage due to the lack of early symptoms, with a high mortality rate and a poor prognosis. The occurrence and development of ccRCC are closely related to metabolic disorders. This study aims to explore the relationship between metabolic genes and prognosis, immune microenvironment, and tumor development of ccRCC. Using data from TCGA, GEO, and ArrayExpress, we successfully established a risk model () based on 4 metabolic genes (MGs) that can accurately predict the prognosis and immune microenvironment of ccRCCs. In addition, we determined the role of PAFAH2 in suppressing tumor cell proliferation and migration in ccRCC in vitro. Our research may shed new light on ccRCC patients' prognosis and treatment management.
透明细胞肾细胞癌（ccRCC）是肾细胞癌（RCC）最常见的亚型。由于缺乏早期症状，许多ccRCC在晚期才被诊断出来，死亡率高且预后较差。ccRCC的发生和发展与代谢紊乱密切相关。本研究旨在探讨代谢基因与ccRCC预后、免疫微环境及肿瘤发展之间的关系。利用来自TCGA、GEO和ArrayExpress的数据，我们成功建立了一个基于4个代谢基因（MGs）的风险模型，该模型可以准确预测ccRCC的预后和免疫微环境。此外，我们确定了PAFAH2在体外抑制ccRCC肿瘤细胞增殖和迁移中的作用。我们的研究可能为ccRCC患者的预后和治疗管理提供新的线索。
Zotero 插件